We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
-15.27%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$3.55B
AUM Growth
-$470M
Cap. Flow
+$314M
Cap. Flow %
8.85%
Top 10 Hldgs %
53.02%
Holding
59
New
5
Increased
5
Reduced
13
Closed
6

Top Buys

Rank Stock Value
1
EQRX
EQRx, Inc. Common Stock
EQRX
+$373M
2
GH icon
Guardant Health
GH
+$81.7M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$21.4M
4
SNCE
Science 37 Holdings, Inc. Common Stock
SNCE
+$20M
5
SEER icon
Seer Inc
SEER
+$18.7M

Top Sells

Rank Stock Value
1
DNA icon
Ginkgo Bioworks
DNA
+$34.1M
2
TWST icon
Twist Bioscience
TWST
+$33.9M
3
EXAS
Exact Sciences
EXAS
+$28.3M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$22.9M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$18.6M

Sector Composition

Rank Sector Weight
1 Healthcare 94.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLFS icon
1
BioLife Solutions
BLFS
$1.56B
$282M 7.95%
7,566,292
– –
EQRX
2
DELISTED
EQRx, Inc. Common Stock
EQRX
$270M 7.6%
+39,527,669
New +$373M
FATE icon
3
Fate Therapeutics
FATE
$294M
$199M 5.61%
3,400,000
– –
NVTA
4
DELISTED
Invitae Corporation
NVTA
$186M 5.25%
12,203,669
– –
ALNY icon
5
Alnylam Pharmaceuticals
ALNY
$29.1B
$170M 4.78%
1,000,000
– –
BPMC
6
DELISTED
Blueprint Medicines
BPMC
$166M 4.68%
1,550,000
– –
PACB icon
7
Pacific Biosciences
PACB
$441M
$163M 4.61%
7,990,652
– –
EXAS
8
DELISTED
Exact Sciences
EXAS
$159M 4.48%
2,040,000
-320,186
-14% -$28.3M
SLGC
9
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$144M 4.06%
12,389,082
– –
MXCT icon
10
MaxCyte
MXCT
$116M
$142M 4.01%
13,971,334
– –
CDXS icon
11
Codexis
CDXS
$157M
$135M 3.82%
4,330,000
– –
SRPT icon
12
Sarepta Therapeutics
SRPT
$1.63B
$122M 3.43%
1,350,000
+250,000
+23% +$21.4M
RLAY icon
13
Relay Therapeutics
RLAY
$4.04B
$118M 3.34%
3,857,253
+188,679
+5% +$5.96M
VERV
14
DELISTED
Verve Therapeutics
VERV
$116M 3.26%
3,138,167
+100,000
+3% +$4.2M
GH icon
15
Guardant Health
GH
$21.6B
$79M 2.23%
+790,000
New +$81.7M
AGIO icon
16
Agios Pharmaceuticals
AGIO
$1.84B
$68.7M 1.94%
2,090,000
-75,000
-3% -$3.02M
TNYA icon
17
Tenaya Therapeutics
TNYA
$161M
$68M 1.92%
3,586,818
– –
DNLI icon
18
Denali Therapeutics
DNLI
$3.67B
$66.9M 1.89%
1,500,000
-200,000
-12% -$9.48M
BEAM icon
19
Beam Therapeutics
BEAM
$2.66B
$65.3M 1.84%
818,820
– –
ABSI icon
20
Absci
ABSI
$1.34B
$63.3M 1.78%
7,718,593
– –
TNGX icon
21
Tango Therapeutics
TNGX
$4.43B
$60M 1.69%
5,487,910
– –
RVMD icon
22
Revolution Medicines
RVMD
$38.8B
$59.7M 1.68%
2,370,000
-430,000
-15% -$12.1M
CDNA icon
23
CareDx
CDNA
$2.48B
$52.5M 1.48%
1,153,335
-40,000
-3% -$2.09M
TWST icon
24
Twist Bioscience
TWST
$5.97B
$51.9M 1.46%
670,000
-330,000
-33% -$33.9M
IPSC icon
25
Century Therapeutics
IPSC
$353M
$50.9M 1.43%
3,206,380
– –
1
2 3

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MIM
Marco Investment Management Atlanta, Georgia $1.33B AUM 32.43% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
MCM
Mill Capital Management Concord, North Carolina $1.31B AUM 17.4% 1-Year Est. Return
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return

Casdin Capital's Q4 2021 Portfolio in Review

As of Q4 2021, Casdin Capital held 59 positions worth $3.55B, down 12% from $4.02B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Casdin Capital deployed $314M of net new capital in Q4 2021, opening 5 new positions and adding to 5 existing holdings. Its largest new stake was EQRx, Inc. Common Stock: 39,527,669 shares worth $270M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 91% a quarter earlier.

On the sell side, the largest reduction was Ginkgo Bioworks, an estimated $34.1M trimmed.

  • Casdin Capital's largest Q4 2021 buy was EQRx, Inc. Common Stock: 39,527,669 shares worth $270M.
  • Casdin Capital added most to Sarepta Therapeutics in Q4 2021, an estimated $21.4M increase.
  • Casdin Capital's biggest Q4 2021 reduction was Ginkgo Bioworks, cutting an estimated $34.1M.
  • Casdin Capital fully exited Syndax Pharmaceuticals in Q4 2021, selling an estimated $22.9M.
  • Casdin Capital's ten largest holdings make up 53% of its $3.55B portfolio in Q4 2021.
  • Casdin Capital opened 5 new positions and closed 6 in Q4 2021.
  • Casdin Capital's portfolio value fell 12% quarter-over-quarter to $3.55B.

Based on Casdin Capital's 13F filing for Q4 2021, filed 14 Feb 2022.